Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow FEMASYS INC

Get SEC filing alerts via email and in your feed for FEMASYS INC

FEMY

FEMASYS INC

About FEMASYS INC

Femasys Inc. develops women’s health solutions, including non-surgical permanent birth control, artificial insemination, and diagnostic devices. Its products serve infertility and contraception markets worldwide, offering minimally invasive, cost-effective alternatives to surgery and traditional treatments. With a strong patent portfolio and regulatory approvals, the company focuses on innovative, in-office medical devices that improve safety, accessibility, and patient satisfaction in reproductive health.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from FEMASYS INC

1
1
FEMASYS INC Femasys Inc. Reports Net Income of $846,100 in Q1 2026, Significant Turnaround from Previous Year

Via official filing (AI summary) | 27 days ago | 0 comments

2
1
FEMASYS INC Femasys Inc. Reports 40.8% Revenue Growth to $2.29 Million for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
FEMASYS INC Femasys Inc. Reports 31.4% Revenue Growth but Incurred $4.2M Net Loss in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
FEMASYS INC Femasys Reports 84.8% Revenue Growth but Faces Continued Net Losses in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
FEMASYS INC Femasys Inc. Reports Q1 2025 Financial Results with Increased Revenue and Net Loss

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
FEMASYS INC Femasys Inc. Reports $18.8 Million Net Loss and 52% Sales Increase for 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
FEMASYS INC Femasys Inc. Reports 127% Revenue Growth, Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments